News

                        Array
(
    [0] => stdClass Object
        (
            [id] => 1297
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => dsc02995.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-04-04
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-04-04 14:15:42
            [updated_time] => 2025-04-21 13:43:53
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => The-role-and-connection-between-clinical-doctors-geneticists-and-genetic-labs-in-diagnosis-and-screening-of-genetic-diseases
            [title] => The role and connection between clinical doctors, geneticists, and genetic labs in diagnosis and screening of genetic diseases
            [description] => In modern medicine, particularly in the diagnosis and screening of genetic diseases, the collaboration between clinical doctors, geneticists, and genetic laboratories plays an extremely important role. This is a closed-loop process that ensures patients receive accurate results, supporting the best treatment and prognosis possible.
            [content] => 
The Importance of Genetic Testing in Diagnosis and Disease Screening 
According to Ms. Katie Battese Ellis (Senior Director of Medical Affairs at Illumina in several APAC countries), in the past, there were not many available tests, so doctors often gathered the patient's characteristics to identify any potential issues. However, with the development of modern medicine, numerous genetic tests are now available, making the diagnosis and screening of diseases easier.
Dr. Pham Dinh Minh, Ms. Katie Battese Ellis, and Associate Prof. Dr. Ho Sy Hung (from left to right) 
With these advancements, we can conduct pre-pregnancy tests to see if both partners are carrying the same genetic condition. Pregnant women can undergo testing to monitor fetal development. Newborn screening tests can also be performed to detect conditions that may affect the health and development of the child later on.
From the test results, geneticists and clinical doctors will discuss and create a plan for better monitoring or treatment for the patient. This not only helps save time and treatment costs but also ensures the health and future happiness of the entire family.
As one of the leading experts in reproductive medicine in Vietnam, Associate Prof. Dr. Ho Sy Hung (Deputy Director of the National Reproductive Support Center) mentioned that the collaboration between genetic experts and clinical doctors is crucial. In reproductive medicine, the success rate of pregnancy is about 50%. However, some patients experience repeated miscarriages for unknown reasons, have a history of genetic diseases, or have undergone multiple IVF cycles without success. These cases require pre-implantation genetic testing (PGT) to select healthy embryos for implantation.
Currently, there are three types of traditional PGT tests: PGT-A, PGT-SR, and PGT-M. PGT-A helps identify normal embryos and increases the chances of success in IVF. PGT-SR can detect unbalanced translocations in embryos before transfer, allowing for the selection of normal embryos, thus increasing the chances of a successful pregnancy. PGT-M is used to screen for monogenic genetic diseases, ensuring that only embryos without genetic mutations are transferred.
GENTIS is a pioneering unit in Vietnam capable of accurately and professionally performing PGT tests with the most advanced techniques, along with a team of highly qualified experts. Notably, GENTIS can screen for about 100 monogenic diseases using PGT-M.

In addition, GENTIS also offers PGT NEXT and PGT UPGRADE with outstanding advantages. PGT NEXT can detect chromosomal abnormalities on all 24 chromosomes, additional abnormalities, chromosomal segment deletions, and aneuploidy. Meanwhile, PGT UPGRADE can detect chromosomal abnormalities, segment deletions, and balanced translocations inherited from parents.
Experts Participating in the Genetic Counseling Talkshow – Discussion with Experts at GENTIS

At GENTIS, PGT testing is conducted in an ISO-standard lab using advanced genetic sequencing methods like NGS, Sanger, or PCR, carried out by skilled technicians and experienced analysts. Afterward, geneticists provide the final conclusions and send them to clinical doctors for patient consultation, ensuring the transfer of healthy embryos into the mother's uterus.
According to Dr. Pham Dinh Minh, genetic and genomic testing is booming in Vietnam. Therefore, GENTIS needs the collaboration between doctors, geneticists, and labs to make genetic tests more accessible and useful, especially in reproductive medicine, obstetrics, and newborn screening.
In the near future, GENTIS will incorporate AI and bioinformatics to screen for more diseases and provide more clinical information to assist doctors in offering the best treatment options for patients.
The Connection Between Clinical Doctors, Geneticists, and Genetic Labs 
The close collaboration between clinical doctors, geneticists, and genetic laboratories is crucial for the effectiveness of disease diagnosis and treatment. According to Ms. Katie, learning and sharing expertise is essential to strengthen cooperation among all parties.
Genetic labs should regularly update new tests, techniques, accuracy, and result turnaround times to ensure that clinical doctors and patients are better informed about the tests. This will help doctors develop the best treatment plan to save costs for patients.
Dr. Minh took Ms. Katie on a tour of the GENTIS testing center

From the clinical doctor's perspective, Associate Prof. Dr. Hung pointed out that genetic issues are challenging for both general clinical doctors and obstetricians in particular. Since tests and techniques in reproductive medicine are constantly developing and changing, continuous learning is necessary to share knowledge and assist patients.
For genetic labs, the quality of testing is the key. Based on test results, doctors can accurately diagnose diseases and develop appropriate treatment plans. Therefore, to bring new, high-quality tests to the market, the support of not only medical experts but also geneticists and technology innovators is essential, as Dr. Minh emphasized.
Based on modern medical advancements and technological progress, genetic testing is increasingly becoming an essential tool for screening and diagnosing diseases. However, to ensure maximum effectiveness, clinical doctors, geneticists, and genetic labs must work closely together. Only by functioning as a unified system can the healthcare system provide the most accurate, personalized, and optimal care for patients.
            [content_more] => 
            [meta_title] =>  The Role and Connection Between Clinical Doctors, Geneticists, and Genetic Labs in Diagnosis and Sc
            [meta_description] => In modern medicine, particularly in the diagnosis and screening of genetic diseases, the collaboration between clinical doctors, geneticists, and genetic laboratories plays an extremely important role. This is a closed-loop process that ensures patients r
            [meta_keyword] => GENTIS,Genetic
            [thumbnail_alt] => 
            [post_id] => 1297
            [category_id] => 4
        )

    [1] => stdClass Object
        (
            [id] => 1296
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => z6465708716299_7722d5faab6d614343abf01d6ab53b54.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2025-04-03
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-04-03 14:29:35
            [updated_time] => 2025-04-17 09:16:27
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Gentis-updated-information-about-2-screening-packages-PGT-NEXT-and-PGT-UPGRADE-at-An-Viet-General-Hospital
            [title] => GENTIS updated information about 2 screening packages: PGT NEXT and PGT UPGRADE at An Viet General Hospital
            [description] => Recently, GENTIS, in collaboration with An Viet General Hospital successfully held a scientific conference aimed at updating the information about 2 new PGT screening packages: PGT NEXT and PGT UPGRADE. At the event, a GENTIS representative provided detailed answers to the questions from doctors at the IVF An Viet Reproductive Center related these two advanced pre-implantation genetic testing packages.
            [content] => 
Attendants at the scientific seminar at An Viet General Hospital included PhD. Dr. Le Minh Chau (Head of the Obstetrics and Gynecology Department at An Viet Hospital), Dr. Mai Thi Giang (Head of the IVF Lab), Dr. Dang Van Ha (Reproductive Support Department), as well as nurses, healthcare staff, and laboratory technicians. From GENTIS, the event saw the presence of MSc. Nguyen Van Huynh (Head of R&D Department at GENTIS) and Ms. Duong Thi Phuong (Head of PM Department at GENTIS)
Throughout the seminar, MSc Huynh provided detailed presentations about PGT NEXT and PGT UPGRADE tests, highlighting the superior features of these two cutting-edge testing solutions.

Regarding PGT NEXT, MSc. Huynh explained that this is an advanced method in in-vitro fertilization (IVF) that analyzes and detects genetic changes in embryos before they are implanted in the uterus. The primary function of this test is to detect genetic disorders, gene mutations, and conditions that could cause health problems for the child or increase the risk of miscarriage.
By using Next-Generation Sequencing (NGS) technology, PGT-NEXT provides higher accuracy compared to traditional testing methods, enabling the selection of healthy embryos, reducing the risk of inherited diseases, and increasing the success rate of pregnancy. This tool is crucial for couples at high genetic risk, offering them a better chance of having a healthy baby. Additionally, this test can be extended to patients with a history of polyploid pregnancies, molar pregnancies, or recurrent miscarriages after undergoing traditional PGT-A IVF, increasing the number of embryos suitable for transfer from fertilized embryos with abnormalities (0PN, 1PN, or 2.1/3PN).
Discussing PGT-UPGRADE, MSc. Huynh mentioned that this is an advanced genetic screening method that detects embryos with balanced translocations. "Balanced translocation is a phenomenon where DNA segments are exchanged between non-homologous chromosomes without increasing or decreasing genetic material at the breakpoints. Balanced translocations are divided into two types: reciprocal translocation and Robertsonian translocation."
Compared to previous traditional PGT methods, PGT-UPGRADE uses NGS technology combined with targeted SNP sequencing, providing higher resolution in detecting aneuploidy, chromosomal structural abnormalities, and complex genetic changes. This method is especially useful for detecting small chromosomal abnormalities and balanced genetic translocations that older methods could not identify, thus helping select healthy embryos, reducing the risk of miscarriage or the birth of children with genetic disorders. PGT-UPGRADE not only increases the success rate of pregnancy but also offers great hope for couples with a history of genetic disorders or recurrent miscarriages, demonstrating its superiority in accuracy and effectiveness over older genetic screening methods.

The seminar took place in a lively atmosphere, receiving positive feedback and interest from the participating doctors. Questions related to PGT-NEXT and PGT-UPGRADE from the doctors of An Viet General Hospital were thoroughly answered by the GENTIS representatives. At the conclusion of the seminar, the doctors at An Viet General Hospital highly appreciated the two advanced tests offered by GENTIS, stating, "These tests are not only a breakthrough in medicine but also bring new rays of hope to couples on their journey to find their beloved child."
GENTIS hopes that after this informative exchange, it will continue to have the opportunity to accompany and collaborate with An Viet Hospital in the future!

            [content_more] => 
            [meta_title] => GENTIS updated information about 2 screening packages: PGT NEXT and PGT UPGRADE at An Viet General H
            [meta_description] => Recently, GENTIS, in collaboration with An Viet General Hospital successfully held a scientific conference aimed at updating the information about 2 new PGT screening packages: PGT NEXT and PGT UPGRADE.
            [meta_keyword] => GENTIS,PGTNEXT,PGTUPGRADE
            [thumbnail_alt] => 
            [post_id] => 1296
            [category_id] => 4
        )

    [2] => stdClass Object
        (
            [id] => 1295
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 487932123_1057582843073573_1848132115822519272_n.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-04-01
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-04-01 08:49:27
            [updated_time] => 2025-04-17 09:14:11
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Happy-motherhood-journey-prenatal-class-equipping-expectant-mothers-with-useful-knowledge
            [title] => "Happy Motherhood Journey" Prenatal Class - Equipping Expectant Mothers with Useful Knowledge
            [description] => Recently, the 5th-floor hall of Hanoi Andrology and Fertility Hospital collaborated with the Happy Home AF HANOI Association successfully chaired the “Happy Motherhood Journey” prenatal class. GENTIS was honored to accompany the event as a sponsor.
            [content] => 
The class attracted participation of more than expectant mothers, bringing a professional and warm ambience filled with valuable insights. The prenatal class featured MSc. Dr. Hoang Van Khanh and specialist doctor level 1 Luu Ba Hung - specialists in Obstetrics and Gynecology at the Hanoi Andrology and Fertility Hospital.

With years of experiences and an amiable sharing style, the two doctors had provided useful answers related to common issues faced during pregnancy. This helped the mothers have better preparations physically and mentally for the journey of pregnancy and childbirth.

During the interactive Q&A section, a lot of practical questions were asked covering topics such as signs of preterm labor, recognizing labor contractions, and concerns regarding nutritions. The doctors not only answered the questions thoughtfully, but also shared real-life stories from their experiences treating expectant mothers, helping them better understand the challenging but joyful journey of motherhood.

The class concluded in a warm and emotional atmosphere. Not only the expectant mothers gained invaluable knowledge, but also they received meaningful gifts from the organizers as a loving reminder of the sacred journey of parenthood. 
In the future, GENTIS, in partnership with the hospital, will continue to organize more prenatal classes to accompany families in preparing a solid foundation for the arrival of their beloved babies.

            [content_more] => 
            [meta_title] => "Happy Motherhood Journey" Prenatal Class - Equipping Expectant Mothers with Useful Knowledge
            [meta_description] => Recently, the 5th-floor hall of Hanoi Andrology and Fertility Hospital collaborated with the Happy Home AF HANOI Association successfully chaired the “Happy Motherhood Journey” prenatal class. GENTIS was honored to accompany the event as a sponsor.
            [meta_keyword] => GENTIS,Prenatal class,Expectant mothers
            [thumbnail_alt] => 
            [post_id] => 1295
            [category_id] => 4
        )

    [3] => stdClass Object
        (
            [id] => 1294
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => dsc02289.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-26
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-26 10:33:26
            [updated_time] => 2025-04-17 09:11:21
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Application-of-pgt-m-tests-in-thalassemia-genetic-disorder-screening
            [title] => Application of PGT-M tests in Thalassemia genetic disorder screening
            [description] => Thalassemia is a recessive inherited anemia disorder on the autosomal chromosome, with the highest incidence rates globally, including in Vietnam. Thalassemia causes severe consequences for the material and mental well-being of affected individuals and their families. Currently, there is no definitive cure for this disease, but proactive prevention and screening are possible. Notably, the advent of Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) helps reduce the risk of having children affected by Thalassemia.
            [content] => 
Thalassemia – A Recessive Genetic Disorder to Be Aware Of
Thalassemia (also known as congenital hemolysis) is the most common single-gene genetic disorder worldwide. According to reports from the Thalassemia Federation and WHO in 2008, approximately 7% of the global population carries the disease gene. For every 100 couples, about 1.1 couples are at risk of having a child with the disease or carrying the Thalassemia gene.
Dr. Le Thao Ly (Quang Ninh Obstetrics and Pediatrics Hospital) reported at the 2025 Clinical Embryology Conference.
In Vietnam, Thalassemia is the leading cause of severe anemia and hemolysis in children. According to the Vietnam Congenital Hemolysis Association, there are about 12 million carriers of the disease gene, and an estimated 20,000 patients need treatment each year.
Couples who carry the Thalassemia gene have a 50% chance of having a child who carries the gene and a 25% chance of having a child with the disease if they conceive naturally. Therefore, couples planning for pregnancy, especially those with a family history of Thalassemia, should take preventive measures for the future generation by undergoing screening for early detection and appropriate preventive actions using PGT-M.
PGT-M Testing Helps Thalassemia-Carrying Parents Have Healthy Children
According to Dr. Le Thao Ly (Quang Ninh Obstetrics and Pediatrics Hospital), who presented at the 6th CEC Conference, PGT-M (Preimplantation Genetic Testing for Monogenic Gene Disorders) was first reported in 1990 and was originally used to diagnose genetic disorders linked to the X chromosome. With this technique, we can examine the genetic makeup of embryos at a very early stage, identifying specific abnormal gene segments inherited from the parents.
As a result, embryos with the disease-causing gene are eliminated before being transferred to the mother's uterus. The effectiveness of this method has been proven to help reduce the incidence of children born with the disease and minimize the need for pregnancy termination.
PGT-M plays a crucial role in reproductive medicine but still presents some challenges.
PGT-M is a test that identifies single-gene abnormalities and mutations related to genetic syndromes such as Thalassemia, Spinal Muscular Atrophy (SMA), Hemophilia, Rett Syndrome, Polycystic Kidney Disease, and others. It is recommended for couples carrying disease-causing gene mutations who are at high risk of having a child with a monogenic genetic disorder.
PGT-M is a highly accurate technique, requiring advanced technology such as SNP (Single Nucleotide Polymorphism) analysis, STR (Short Tandem Repeat) analysis, qPCR (real-time PCR), MLPA (Multiplex Ligation-dependent Probe Amplification), or NGS (Next-Generation Sequencing), depending on the specific monogenic disorder to be analyzed. The goal is to detect gene mutations that the parents carry and can pass on to their child.
To perform PGT-M, couples typically need reproductive assistance through in vitro fertilization (IVF). Embryos created through IVF are cultured until day 5. Embryos at this stage (blastocysts) are biopsied, and 5-7 cells are extracted from the part of the embryo that will develop into the placenta. These cell samples undergo special tests to identify the disease-causing genes.
This test enables doctors to check the genetic makeup of the embryos at an early stage, allowing for the identification and removal of embryos carrying the parents' genetic disease. Only healthy embryos are transferred to the mother's uterus, increasing the chances of pregnancy and resulting in healthy children who do not carry genetic mutations for future generations.
To date, in addition to screening for Thalassemia PGT-M, GENTIS has also developed PGT-M techniques for over 100 rare genetic disorders, including Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, Hemophilia, Congenital Adrenal Hyperplasia, and more.
PGT-M Testing at GENTIS is Performed Using a Rigorous, Professional Process
Along with the application of new technologies and advanced machinery systems (Veriseq PGS technology, Illumina NGS DNA sequencing system from the USA, and SNP, STR analysis methods), PGT-M testing at GENTIS is carried out in a strict, professional manner to ensure highly reliable results. Combining PGT-M screening for monogenic genetic disorders with PGT-A/SR testing before PGT-M helps provide a comprehensive assessment of embryo quality, improving the success rate of assisted reproductive methods.
            [content_more] => 
            [meta_title] => Application of PGT-M tests in Thalassemia genetic disorder screening
            [meta_description] => Thalassemia is a recessive inherited anemia disorder on the autosomal chromosome, with the highest incidence rates globally, including in Vietnam. Thalassemia causes severe consequences for the material and mental well-being of affected individuals and th
            [meta_keyword] => GENTIS,Thalassemia,PGT-M
            [thumbnail_alt] => 
            [post_id] => 1294
            [category_id] => 4
        )

    [4] => stdClass Object
        (
            [id] => 1293
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 79de34c95adeea80b3cf.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-25
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-25 08:43:38
            [updated_time] => 2025-04-15 14:58:16
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => PGT-M-for-100+-rare-diseases-a-solution-for-healthy-babies-in-families-carrying-genetic-disorders
            [title] => PGT-M for 100+ Rare Diseases: A Solution for Healthy Babies in Families Carrying Genetic Disorders
            [description] => Rare diseases often lead to serious health complications and significantly affect a patient’s quality of life. Therefore, the development of PGT-M testing to screen and select embryos free of rare disease-causing genes for implantation is essential. In an effort to eliminate the fear of rare diseases from the community, GENTIS has researched and developed a PGT-M test capable of screening for over 100 rare diseases.
            [content] => 
Rare Diseases – A Group That Demands Attention
Rare diseases are conditions that occur infrequently in the general population, usually caused by genetic mutations, and often have a severe impact on a patient’s health. According to the World Health Organization (WHO), a disease is considered rare when it affects fewer than 1 in 2,000 people. While each disease is rare individually, over 7,000 rare diseases have been identified, affecting approximately 300 million people worldwide.
These diseases are typically serious due to their complex nature and the lack of effective treatments. Many manifest severely from birth, leading to congenital defects, developmental delays, high mortality rates, or lifelong disabilities. Because of the low prevalence, developing treatments and diagnostics remains a major challenge, limiting access to care.
However, advancements in genetics, assisted reproduction, and prenatal diagnostics have expanded our ability to screen and manage rare diseases, offering hope for couples wanting to conceive and give birth to healthy children.
PGT-M for 100+ Rare Diseases: Bringing Hope to Families with Genetic Risks
In clinical practice and research, medical genetics plays an increasingly vital role. Preimplantation Genetic Testing for Monogenic Disorders (PGT-M), combined with assisted reproductive technologies, has brought joy to many infertile couples by allowing them to have healthy children and contribute to reducing the incidence of monogenic rare diseases in the community.
PGT-M is performed during in vitro fertilization (IVF) and is used to detect and select embryos free from disease-causing genetic mutations before embryo transfer into the uterus
GENTIS Utilizes Modern Technologies for PGT-M Testing
PGT-M plays a key role in screening and preventing rare diseases, especially in couples with a family history of genetic conditions. By ensuring that only embryos without the disease-causing gene are transferred, this test not only reduces the burden of genetic disease on families but also improves the overall health of future generations.
Applying PGT-M in assisted reproduction marks a significant breakthrough in medicine, offering hope and a path forward for couples who wish to have healthy children, while reducing the risk of passing on rare genetic diseases.
At GENTIS, PGT-M can detect over 100 rare diseases caused by gene mutations, helping minimize the risk of giving birth to a child with a severe genetic disorder.
A Highly Skilled Team at GENTIS
Outstanding Advantages of the PGT-M Test for 100+ Rare Diseases:
This specialized test not only brings hope to couples carrying genetic disorders but also offers multiple advantages for optimizing genetic screening right from the embryonic stage.
One of the most significant benefits of GENTIS’s PGT-M test is the ability to accurately analyze over 100 monogenic disorders, capable of detecting even subtle variations in DNA that may cause disease.
Using next-generation sequencing (NGS) technology combined with customized family-specific marker design, PGT-M ensures precise identification of healthy embryos, increasing the chances of a successful, healthy pregnancy.
Additionally, the PGT-M service for 100+ rare diseases is supported by a team of expert genetic counselors, who guide patients before, during, and after the testing process.
Expert-Led, Patient-Centered Genetic Counseling at GENTIS
Before testing, counselors help couples understand their genetic risks, explain disease mechanisms, and assess the necessity of the test. Throughout the testing process, experts closely monitor each stage to ensure result accuracy and appropriateness.
After results are available, the team continues to provide support by interpreting clinical implications, guiding couples in selecting the best embryos, and proposing tailored reproductive strategies if necessary.
Thus, PGT-M is more than a screening tool — it is a comprehensive solution, offering peace of mind to families at risk of transmitting genetic conditions.
According to Assoc. Prof. Dr. Francesca Spinella (Former Chair of the ESHRE PGT Consortium and Genetic Consultant at Eurofins GENTIS), PGT-M plays a vital role in the field of reproductive medicine. This test allows for the screening of monogenic disorders and ensures that only embryos without genetic mutations are transferred — bringing hope to couples struggling with infertility and genetic risks.
            [content_more] => 
            [meta_title] => PGT-M for 100+ Rare Diseases: A Solution for Healthy Babies in Families Carrying Genetic Disorders
            [meta_description] => Rare diseases often lead to serious health complications and significantly affect a patient’s quality of life. Therefore, the development of PGT-M testing to screen and select embryos free of rare disease-causing genes for implantation is essential
            [meta_keyword] => GENTIS,pgt-m
            [thumbnail_alt] => 
            [post_id] => 1293
            [category_id] => 4
        )

    [5] => stdClass Object
        (
            [id] => 1292
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => dsc02511.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-24
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-24 16:00:41
            [updated_time] => 2025-04-15 14:52:29
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => GENTIS-accompanies-the-2025-clinical-embryology-conference
            [title] => GENTIS Accompanies the 2025 Clinical Embryology Conference
            [description] => Clinical embryology and issues related to the IVF lab play a vital role in the advancement of Assisted Reproductive Technology (ART). The 6th Clinical Embryology Conference (CEC), organized by the Ho Chi Minh City Society for Reproductive Medicine (HOSREM), will be held on March 22–23, 2025. The conference aims to provide opportunities for professional updates, knowledge exchange, and the presentation of scientific research in the field of clinical embryology. GENTIS is honored to be a sponsor of this important event.
            [content] => 
At the conference, leading experts in IVF will present and discuss various issues related to clinical embryology and IVF laboratories. Some of the key topics covered include:


Quality management and new techniques



Embryo genetic testing


Sperm-related factors


Poor prognosis cases


Embryo culture and cryopreservation


Embryos from abnormal fertilization and abnormal oocytes



Notably, GENTIS is proud to have provided PGT-M testing data for the presentation by Resident Doctor Lê Thảo Ly (Quang Ninh Obstetrics and Pediatrics Hospital), titled: "Evaluating the Live Birth Rate Following Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) for Thalassemia at Quang Ninh Obstetrics and Pediatrics Hospital from 2022–2024."
According to Dr. Thảo Ly, Thalassemia is the most common autosomal recessive inherited anemia worldwide, including in Vietnam. This disease significantly impacts the physical and mental well-being of patients and their families. While there is currently no definitive cure, it can be proactively prevented and screened. Importantly, the introduction of PGT-M has helped reduce the risk of giving birth to children affected by Thalassemia.
At GENTIS, the PGT-M test is conducted using cutting-edge technologies and modern equipment, including Veriseq PGS, next-generation sequencing (NGS) with Illumina technology (USA), and SNP/STR analysis methods. This ensures the high reliability of test results. Currently, GENTIS is capable of screening for more than 100 monogenic diseases using PGT-M.

As a sponsor of the conference, GENTIS presented an impressive booth with a variety of engaging activities, drawing great interest from many delegates. Highlights included:


Introducing advanced, modern solutions for preimplantation embryo genetic screening tailored to improve healthcare outcomes for the Vietnamese population, particularly two new PGT testing packages: PGT NEXT and PGT UPGRADE



Providing the latest genetic testing materials in the field of assisted reproduction


Offering attractive appreciation gifts to participating delegates



Over the years, GENTIS has regularly participated in conferences and seminars to stay updated with the latest insights, technologies, and advancements in IVF. Our goal is to provide effective and accurate genetic testing for patients.
The 2025 Clinical Embryology Conference concluded successfully, offering a wealth of knowledge, clinical expertise, and updates on trends, technologies, and treatment protocols. It also signals promising growth in Vietnam’s reproductive health sector in the years ahead.
            [content_more] => 
            [meta_title] => GENTIS Accompanies the 2025 Clinical Embryology Conference
            [meta_description] => Clinical embryology and issues related to the IVF lab play a vital role in the advancement of Assisted Reproductive Technology (ART). The 6th Clinical Embryology Conference (CEC), organized by the Ho Chi Minh City Society for Reproductive Medicine (HOSREM
            [meta_keyword] => gentis,CEC
            [thumbnail_alt] => 
            [post_id] => 1292
            [category_id] => 4
        )

    [6] => stdClass Object
        (
            [id] => 1291
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => fd00c58f1d82addcf493.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-24
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-24 15:16:39
            [updated_time] => 2025-04-15 14:49:11
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Recommendation-on-mutation-confirmation-prior-to-performing-preforming-preimplantation-genetic-testing-for-monogenic-diseases-PGT-M
            [title] => 
            [description] => GENTIS is a pioneer in the field of genetic analysis, providing the best and most advanced services and tests to customers and partners with the goal of enhancing the physical and intellectual well-being of the Vietnamese people — including PGT-M testing.

            [content] => 
PGT-M (Preimplantation Genetic Testing for Monogenic diseases) is a genetic screening test performed on embryos to identify and select embryos that do not carry disease-causing genetic mutations inherited from the parents. This test is typically recommended for couples who are carriers of mutations linked to genetic disorders and wish to prevent passing these conditions on to their children. As it is performed before embryo transfer, this early screening method helps avoid the risk of children being born with genetic diseases and reduces the need for pregnancy termination due to severe genetic abnormalities.
To ensure accuracy and compatibility with GENTIS' testing protocols, and to protect customer rights during the PGT-M testing process, we issue the following recommendations regarding the submission of genetic test results before performing PGT-M:


In cases where genetic test results are provided from a family member affected by the condition (e.g., children, siblings, etc.), mutation confirmation in the couple intending to undergo PGT-M is MANDATORY.


In cases where genetic test results are provided from the couple intending to undergo PGT-M:


If the test was performed at GENTIS: The result is accepted for use in PGT-M, and GENTIS takes full responsibility for the accuracy of this result.


If the test was performed at another laboratory: Sanger sequencing data must be provided, or it is recommended that mutation confirmation be redone at GENTIS.




Why does GENTIS require mutation confirmation in parents before performing PGT-M?


Commitment to quality and medical responsibility: GENTIS is fully accountable for the results of tests it performs. We cannot guarantee the accuracy of tests conducted by third parties.


The genetic test results directly impact the PGT-M process and its outcomes.


Ensuring customer rights during PGT-M testing: Confirming the mutation in the couple allows doctors to make appropriate decisions regarding PGT-M, preventing scenarios where patients undergo an IVF cycle but cannot proceed with PGT-M due to inadequate testing.




Important Recommendation 
If you are considering PGT-M testing, we strongly recommend that it be performed directly at GENTIS to ensure the highest level of accuracy, consistency, and compatibility with your treatment plan.
Contact GENTIS' expert team to have all your questions answered before proceeding with testing.
 GENTIS is committed to providing accurate, safe, and optimized testing services — ensuring a complete and satisfying experience for our clients.
GENTIS HOTLINE: 1800 2010
 Website: gentis.com.vn


            [content_more] => 
            [meta_title] => Recommendation on Mutation Confirmation Prior to Performing Preimplantation Genetic Testing for Mono
            [meta_description] => GENTIS is a pioneer in the field of genetic analysis, providing the best and most advanced services and tests to customers and partners with the goal of enhancing the physical and intellectual well-being of the Vietnamese people — including PGT-M testing.
            [meta_keyword] => GENTIS,PGT-M
            [thumbnail_alt] => Recommendation on Mutation Confirmation Prior to Performing Preimplantation Genetic Testing for Monogenic Diseases (PGT-M)
            [post_id] => 1291
            [category_id] => 4
        )

    [7] => stdClass Object
        (
            [id] => 1290
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => b7db2d93bf200e7e5731.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-18
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-18 15:58:16
            [updated_time] => 2025-03-18 16:03:00
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/gentis-gioi-thieu-xet-nghiem-pgt-next-va-pgt-upgrade-tai-benh-vien-buu-dien-d1290
            [title] => GENTIS introduces 2 new PGT test packages at Hospital of Post and Telecommunications
            [description] => On the afternoon of March 6, GENTIS coordinated with the Post Office Hospital to organize a seminar introducing two newly launched PGT testing packages: PGT NEXT and PGT UPGRADE. Throughout the seminar, GENTIS representatives discussed and answered questions from doctors at the Post Office Hospital about these new genetic testing packages.
            [content] => 
Attending the seminar, on behalf of the IVF Center, the Post Office Hospital had the presence of Master. Doctor Bach Huy Anh (Deputy Director), Master. Doctor Chu Thi Huong, Doctor CKI. Kieu Duc Ty and doctors of the department. Representing GENTIS, there was the participation of Mr. Nguyen Quang Vinh (Director of Testing Center) and Mr. Nguyen Van Huynh (Leader of R&D).
Mr. Vinh and Mr. Huynh gave a detailed introduction to the two test packages PGT NEXT and PGT UPGRADE of GENTIS. Sharing with the doctors of the HTSS Center - Post Office Hospital, Mr. Huynh emphasized the technological breakthrough of both new PGT tests.

Accordingly, the PGT NEXT test is a test that can detect haploid/polyploid embryos. According to statistics during the research process at GENTIS: "Haploid/polyploid abnormalities occur in 1-3% of all pregnancies and triploidy accounts for 15-18% of miscarriages." Therefore, detecting haploid/polyploid embryos is highly significant in increasing the success rate of IVF.
In addition, PGT NEXT also supports and complements PGT-A/SR, helping to detect polyploid embryos and identify embryos with normal diploid chromosome sets, even in abnormally fertilized embryos (e.g., 0PN, 1PN, or 2.1/3PN).
This test can be extended to patients with a history of polyploidy, molar pregnancy, and miscarriage after IVF combined with traditional PGT-A, increasing the number of embryos that can be transferred from abnormally fertilized zygotes (0PN, 1PN, or 2.1/3PN). The implementation process combines whole genome sequencing NGS (Low-pass sequencing) with targeted SNP sequencing to detect polyploidy.

For PGT UPGRADE, this is a test to detect embryos carrying balanced translocations. "Balanced translocation is the phenomenon of exchanging DNA segments between non-homologous chromosomes without increasing or decreasing genetic material at the breakpoints. In balanced translocation, there are also two types: Reciprocal translocation and Robertsonian translocation."
The PGT UPGRADE test is indicated for couples with a history of recurrent miscarriage, a family history of chromosomal abnormalities, or spouses carrying balanced translocations who do not want to pass them on to the next generation. The implementation process combines whole genome sequencing NGS (Low-pass sequencing) with targeted SNP sequencing to detect embryos carrying balanced translocations.
The outstanding advantage of the PGT NEXT and PGT UPGRADE tests is the use of specialized bioinformatics software optimized specifically for the Vietnamese population. Therefore, these two tests not only help detect genetic abnormalities but also help reduce the risk of miscarriage, increase the success rate of in vitro fertilization (IVF) and help select healthy embryos to be placed in the uterus.

At the end of the presentation, doctors at the Post Office Hospital asked many questions about PGT NEXT and PGT UPGRADE, specifically: "Is 18% of the total number of embryos the proportion of euploid embryos carrying balanced translocations?", "With this new technology, is the cost of performing PGT UPGRADE much higher than the cost of performing PGT-A?". Thanks to the detailed answers of the GENTIS representative, the doctors had a clearer view and could visualize the future development of the PGT NEXT and PGT UPGRADE tests.

The seminar took place in a very exciting atmosphere and received a lot of attention and positive feedback from the participating doctors. Master, Doctor Bach Huy Anh shared: "Thank you GENTIS for coming to our hospital today and updating new products that are extremely meaningful and highly practical. For me personally, the PGT UPGRADE test has a high humanitarian significance, helping couples with balanced translocation genes prevent the possibility of passing it on to future generations. I believe that in the future, these two tests will greatly support infertile couples with multiple miscarriages, helping them reach their dream of becoming parents."
            [content_more] => 
            [meta_title] => GENTIS introduces 2 new PGT test packages at Hospital of Post and Telecommunications
            [meta_description] => On the afternoon of March 6, GENTIS coordinated with the Post Office Hospital to organize a seminar introducing PGT NEXT and PGT UPGRADE.
            [meta_keyword] => gentis,Pgtnext,Pgtupgrade
            [thumbnail_alt] => 
            [post_id] => 1290
            [category_id] => 4
        )

)